{"filing":{"accession_number":"0001404644-26-000050","cik":"0001404644","ticker":"NGNE","company_name":"Neurogene Inc.","form":"8-K","filing_date":"2026-07-01","report_date":null,"primary_document":"ngne-20260630.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1404644/000140464426000050/ngne-20260630.htm"},"events":[{"id":15636,"run_id":13940,"accession_number":"0001404644-26-000050","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Neurogene entered into an underwriting agreement to issue 3.5 million shares of common stock at $30.00 per share, plus 666,666 pre-funded warrants, with underwriters exercising a full 30-day option for an additional 624,999 shares, expected to raise approximately $134.8 million in net proceeds.","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-07-01","form":"8-K","submitted_at":null,"items":[{"id":13490,"accession_number":"0001404644-26-000050","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Neurogene entered into an underwriting agreement to issue 3.5 million shares of common stock at $30.00 per share, plus 666,666 pre-funded warrants, with underwriters exercising a full 30-day option for an additional 624,999 shares. The offering is expected to raise approximately $134.8 million in net proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:05:38.988248+00:00","company_name":"","ticker":null,"filing_date":""},{"id":13491,"accession_number":"0001404644-26-000050","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The disclosure addresses the Company's liquidity runway and capital sufficiency following an offering, projecting cash adequacy through Q1 2029. While this is a financial statement regarding cash resources and operating capacity, it does not fit the specific categories of debt issuance, dividend distribution, or material impairment. The reference to \"net proceeds from the Offering\" suggests a capital raise event, but the Item 8.01 text itself focuses on the resulting liquidity position rather than the offering mechanics, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:05:38.988248+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13490,"accession_number":"0001404644-26-000050","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Neurogene entered into an underwriting agreement to issue 3.5 million shares of common stock at $30.00 per share, plus 666,666 pre-funded warrants, with underwriters exercising a full 30-day option for an additional 624,999 shares. The offering is expected to raise approximately $134.8 million in net proceeds. This is a material dilutive equity issuance that would significantly affect shareholder ownership percentages and is material to investors assessing the company's capital structure and financing activities.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:05:38.988248+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-07-01"},{"id":13491,"accession_number":"0001404644-26-000050","item_number":"8.01","item_title":null,"event_type":"financial_other","event_domain":"financial","is_material":true,"confidence":0.72,"reasoning":"The disclosure addresses the Company's liquidity runway and capital sufficiency following an offering, projecting cash adequacy through Q1 2029. While this is a financial statement regarding cash resources and operating capacity, it does not fit the specific categories of debt issuance, dividend distribution, or material impairment. The reference to \"net proceeds from the Offering\" suggests a capital raise event, but the Item 8.01 text itself focuses on the resulting liquidity position rather than the offering mechanics, making financial_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:05:38.988248+00:00","company_name":"Neurogene Inc.","ticker":"NGNE","filing_date":"2026-07-01"}]}